Henry O Gosebruch has bought stock on 4 days since May 2019

Henry O. Gosebruch is a biopharmaceutical executive and corporate insider who served as President and Chief Executive Officer of Neumora Therapeutics, Inc. (Nasdaq: NMRA) from July 2023 until February 2025.( At Neumora, a clinical-stage neuroscience-focused biopharmaceutical company, he led corporate strategy and operations through the company’s IPO and advancement of its brain disease pipeline, before departing as part of a leadership transition in which co-founder Paul L. Berns returned to the CEO role.( During his tenure, SEC filings identified him as "Henry O. Gosebruch" in his capacity as Chief Executive Officer and as a party to Neumora’s executive employment and separation agreements.(

Gosebruch brings over 25 years of pharmaceutical, strategy, and deal-making experience to his leadership roles.( Prior to Neumora, he was Executive Vice President and Chief Strategy Officer at AbbVie Inc., where he oversaw corporate strategy and long-range planning across all therapeutic franchises, including neuroscience and external innovation.( Earlier, he spent two decades in Mergers & Acquisitions at J.P. Morgan, rising to Co-Head of M&A North America.( He has also served on the board of Acelyrin, Inc., chairing its Compensation Committee and sitting on the Audit Committee.( As of 2025, he is CEO of Lakefront Biotherapeutics (Lakefront Bio) and previously acted as founding CEO of a Galapagos NV spinout.( Gosebruch holds a BSE in Finance and Management from the Wharton School of the University of Pennsylvania and is a Certified Public Accountant in Illinois, and he serves on the Advisory Board for Penn’s Life Sciences & Management Program.(

Written by Perplexity from public sources.